MX374759B - Inhibidores de tirosina cinasa de bruton. - Google Patents
Inhibidores de tirosina cinasa de bruton.Info
- Publication number
- MX374759B MX374759B MX2016006351A MX2016006351A MX374759B MX 374759 B MX374759 B MX 374759B MX 2016006351 A MX2016006351 A MX 2016006351A MX 2016006351 A MX2016006351 A MX 2016006351A MX 374759 B MX374759 B MX 374759B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- btk
- bruton
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000003844 B-cell-activation Effects 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta solicitud describe compuestos de acuerdo con la fórmula genérica (I): en donde todas las variables se definen como se describe en el presente documento, que inhiben Btk. Los compuestos descritos en el presente documento son útiles para modular la actividad de Btk y tratar enfermedades asociadas con exceso de actividad Btk. Los compuestos son útiles para el tratamiento de enfermedades oncológicas, autoinmunes, e inflamatorias causadas por la activación de células B aberrante. También se describen composiciones que contienen compuestos de Fórmula I y por lo menos un portador, diluyente o excipiente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915588P | 2013-12-13 | 2013-12-13 | |
| PCT/EP2014/077116 WO2015086636A1 (en) | 2013-12-13 | 2014-12-10 | Inhibitors of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006351A MX2016006351A (es) | 2016-08-01 |
| MX374759B true MX374759B (es) | 2025-03-06 |
Family
ID=52016583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006351A MX374759B (es) | 2013-12-13 | 2014-12-10 | Inhibidores de tirosina cinasa de bruton. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9802920B2 (es) |
| EP (1) | EP3080098B1 (es) |
| JP (1) | JP6294490B2 (es) |
| KR (1) | KR101822767B1 (es) |
| CN (1) | CN105722834B (es) |
| BR (1) | BR112016013541B1 (es) |
| CA (1) | CA2929785C (es) |
| MX (1) | MX374759B (es) |
| RU (1) | RU2653500C2 (es) |
| TW (1) | TWI540130B (es) |
| WO (1) | WO2015086636A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9624201B2 (en) * | 2013-12-13 | 2017-04-18 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
| JP6762300B2 (ja) | 2015-06-17 | 2020-09-30 | 中外製薬株式会社 | アミノピラゾール誘導体 |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| US20030236288A1 (en) | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| CN1934074A (zh) | 2003-06-24 | 2007-03-21 | 尤尼罗亚尔化学公司 | 杀真菌的苯氧基苯肼衍生物 |
| CN1832928B (zh) | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| FR2892416B1 (fr) | 2005-10-20 | 2008-06-27 | Sanofi Aventis Sa | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique |
| JP2009516702A (ja) | 2005-11-18 | 2009-04-23 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| US8026257B2 (en) | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| HRP20151258T1 (hr) * | 2009-08-07 | 2016-02-26 | Chugai Seiyaku Kabushiki Kaisha | Derivat aminopirazola |
| BR112012006630A2 (pt) | 2009-09-24 | 2016-05-03 | Hoffmann La Roche | derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| US9840515B2 (en) | 2010-12-09 | 2017-12-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Protein kinase D inhibitors |
| JP5620417B2 (ja) | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
-
2014
- 2014-12-10 KR KR1020167015254A patent/KR101822767B1/ko not_active Expired - Fee Related
- 2014-12-10 EP EP14809643.1A patent/EP3080098B1/en active Active
- 2014-12-10 US US15/102,043 patent/US9802920B2/en not_active Expired - Fee Related
- 2014-12-10 MX MX2016006351A patent/MX374759B/es active IP Right Grant
- 2014-12-10 RU RU2016125825A patent/RU2653500C2/ru active
- 2014-12-10 CA CA2929785A patent/CA2929785C/en active Active
- 2014-12-10 JP JP2016539189A patent/JP6294490B2/ja not_active Expired - Fee Related
- 2014-12-10 WO PCT/EP2014/077116 patent/WO2015086636A1/en not_active Ceased
- 2014-12-10 CN CN201480061609.8A patent/CN105722834B/zh not_active Expired - Fee Related
- 2014-12-10 BR BR112016013541-5A patent/BR112016013541B1/pt not_active IP Right Cessation
- 2014-12-11 TW TW103143356A patent/TWI540130B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016540023A (ja) | 2016-12-22 |
| EP3080098A1 (en) | 2016-10-19 |
| JP6294490B2 (ja) | 2018-03-14 |
| RU2653500C2 (ru) | 2018-05-10 |
| TW201536773A (zh) | 2015-10-01 |
| WO2015086636A1 (en) | 2015-06-18 |
| US20160304497A1 (en) | 2016-10-20 |
| HK1226070B (zh) | 2017-09-22 |
| KR101822767B1 (ko) | 2018-01-26 |
| CA2929785A1 (en) | 2015-06-18 |
| CA2929785C (en) | 2018-02-13 |
| US9802920B2 (en) | 2017-10-31 |
| MX2016006351A (es) | 2016-08-01 |
| BR112016013541B1 (pt) | 2021-03-02 |
| TWI540130B (zh) | 2016-07-01 |
| CN105722834A (zh) | 2016-06-29 |
| KR20160081982A (ko) | 2016-07-08 |
| CN105722834B (zh) | 2017-12-22 |
| EP3080098B1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX380907B (es) | Compuestos útiles como inhibidores de cinasa. | |
| SG194728A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12014500128A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX374758B (es) | Inhibidores de tirosina cinasa de bruton. | |
| BR112015032595A2 (pt) | inibidores de ido | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| EA201691514A1 (ru) | Соединения | |
| GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
| MX2015005015A (es) | Inhibidores heteroarilo de pde4. | |
| GEP20166554B (en) | Nitrogenated heterocyclic compound | |
| MX2015012056A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| WO2014064131A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. | |
| MX2018007075A (es) | Compuestos policiclicos como inhibidores de tirosina quinasa de bruton. | |
| MX2015010466A (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX370010B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| EA201790207A1 (ru) | Новые замещенные пиримидиновые соединения | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| EA201590379A1 (ru) | Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: F. HOFFMANN-LA ROCHE AG |
|
| FG | Grant or registration |